Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma.

This is the first report of pediatric linear scleroderma successfully treated with the topical Janus kinase (JAK) inhibitor delgocitinib. JAK inhibitors targeting the JAK/STAT pathway have been used to treat various immune-mediated diseases. In both in vitro and in vivo, JAK inhibitors also block the transforming growth factor (TGF)-β-mediated effects that contribute to skin sclerosis.

Papuloerythroderma-like cutaneous involvement of a CD62L subclone of T-cell prolymphocytic leukemia.

We report the case of an 88-year-old Japanese man with erythrodermic involvement of T-cell prolymphocytic leukemia (T-PLL). He had a history of pharyngeal diffuse large B-cell lymphoma successfully treated with polychemotherapy including cyclophosphamide and epirubicin, 6 years before the current illness. He presented with numerous reddish, coalescing, flat-topped papules on the trunk and extremities, sparing the skin folds of the abdomen, the features of which mimicked those of papuloerythroderma.

Ultrasonographic measurement of bladder wall thickness as a risk factor for upper urinary tract deterioration in children with myelodysplasia.

Purpose: We investigated the correlations between ultrasonographic bladder wall thickness and urodynamic parameters, and estimated the diagnostic accuracy of bladder wall thickness for predicting unfavorable urodynamic patterns in children with myelodysplasia.

Materials And Methods: A total of 57 children (median age 5.1 years) with myelodysplasia were enrolled in the study.

Establishment of a newly improved detection system for NF-kappaB activity.

The transcription factor nuclear factor-kappaB (NF-kappaB) plays roles in apoptosis, inflammation and oncogenesis. It is important for biological and medical research to understand when proteins of interest are activated in cells, leading to the establishment of a luciferase/EGFP assay to monitor the activation of transcription factors. Here, we describe an improved reporter system for NF-kappaB, the NF-kappaB-activated transgene (NAT) system that can detect NF-kappaB signalling with high sensitivity and specificity.